RZLT · sample dossier
Rezolute, Inc. Common Stock (NV)
42/100
OutdatedGenerated Sep 12, 2026 · 10:00 AM UTC · 55 days ago
This copy is frozen (Sep 12). Sign in to run the same work — filings, valuation, bull and bear, sources — on any US stock or ETF, in about 90 seconds.
Run a fresh dossierRZLT
EquityRezolute, Inc. Common Stock (NV) · XNAS
Decision context
Recommendation
Weighed down by weak Quality (13/100) and Value (43/100) scores.
A mixed picture — no strong reason to buy or sell right now.
AlphaDog Fair Value
Executive thesis & key metrics
Executive Investment Thesis
Rezolute, Inc. is a clinical-stage biopharmaceutical company with a market capitalization of $406.35M and a Price/Book ratio of 3.77. Operating performance shows severe pre-commercial constraints with 0.0% gross margin, 0.0% net margin, an ROA of -48.7%, and an FCF/share of -$0.45. The primary risk confronting the equity is substantial capital dilution reflected in a 48.6% YoY increase in common shares outstanding, reinforced by an explicit going-concern assessment in its 2026-05-12 Form 10-Q filing.
Key Metrics to Watch
What changed recently
No material changes found in the last 30 days.
Why this rating
Score 42 · Hold
Data through
OutdatedMar 31, 2026
Composite 42/100 — no single factor above 75 dominates.
Levels unavailable — AlphaDog quantitative valuation model did not produce an estimate from comps or DCF
Re-evaluate if
- Severe accounting disclosures (auditor / restatement / going concern) in SEC filings
- Net margin falls below 0.0% (was 0.0%)
- Debt/Equity increases above 0.01.
Trim / reconsider if
- ROA deteriorates below -48.7%
- Debt/Equity increases above 0.01.
Think of these dollars as a map of our value estimate for Hold — helpful context, not a reason to override the view.
A Calmer Look · Devil's Advocate
The prevailing consensus unanimously concludes 'Avoid' based on severe equity dilution (+48.6% YoY) and an active going-concern warning, yet this view misinterprets standard pre-commercial biotech capital structures.
May be overlooked
The bear consensus anchors its solvency panic on a Form 10-Q going-concern disclosure from 2026-05-12, which is 123 days old and stale under the 90-day threshold, ignoring balance sheet changes across subsequent Form 8-K filings on 2026-05-12 and 2026-06-02.
The consensus treats the 48.6% YoY expansion in shares outstanding purely as shareholder destruction, overlooking that it fully eliminated debt obligations to achieve a Debt/Equity ratio of 0.01 and an Altman Z-score of 19.13.
The analysis fails to account for institutional conviction, ignoring why prominent life-sciences funds Federated Hermes (12,990,659 shares) and RA Capital Management (9,445,039 shares) maintain concentrated long positions despite $-0.45 FCF/share burn.
Expectations look stretched
Bulls extrapolate positive intermediate 6-month price momentum of 39.7% and trading above the 200-day moving average while ignoring a -47.9% 1-year loss and a -10.2% 1-month drop below the 50-day moving average.
Bulls cite an Altman Z-score of 19.13 as evidence of structural balance sheet safety, failing to note that this metric is distorted by equity market valuation against a weak Piotroski F-score of 4/9.
Bears extrapolate standard pre-commercial clinical metrics (0.0% gross margin, 0.0% net margin, and -48.7% ROA) as proof of terminal operational insolvency rather than routine R&D pipeline progress.
Debt/Equity increases above 0.01.
Debt/Equity increases above 0.01.
Market context
Snapshot returns at report publication
1 month
-10.2%
3 months
+9.3%
6 months
+39.7%
1 year
-47.9%
At a Glance
A smaller company has mixed momentum at unprofitable earnings.
Top Holders
Financial trajectory
Go deeper
For learning and research only — not investment advice. AlphaDog doesn’t hold stocks and isn’t your financial advisor.
Run the next one yourself.
You just read a full RZLT dossier — scored verdict, valuation, and both sides, with sources. Sign in to run that on a name you hold, on current filings. A free account includes 10 credits a week, 1 per fresh run.